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RESEARCH ARTICLE Open Access
A 5 item version of the Compliance Questionnaire
for Rheumatology (CQR5) successfully identifies
low adherence to DMARDs
Lyndsay D Hughes1,2*, John Done2 and Adam Young3
Abstract
Background: Taking DMARDs as prescribed is an essential part of self-management for patients with Rheumatoid
Arthritis. To date, the Compliance Questionnaire for Rheumatology (CQR) is the only self-report adherence measure
created specifically for and validated in rheumatic diseases. However, the factor structure of the CQR has not been
reported and it can be considered lengthy at 19 items. The aim of this study was to test the factor structure of the
CQR and reduce the number of items whilst retaining robust explanation of non-adherence to DMARDs. Such a
reduction would increase the clinical utility of the scale, to identify patients with sub-optimal adherence to
DMARDs in the clinic as well as for research purposes.
Methods: An exploratory factor analysis was performed to reduce the number of items in the CQR and then a
confirmatory factor analysis was run to establish the fit of a 5 item version (CQR5) to the data. A discriminant
function analysis was performed to determine the optimal combination of questions to identify suboptimal
adherence.
Results: The factor analyses identified a unidimensional 5 item model that explains 50.3% of the variance in
adherence and has good internal consistency and fit to the data. Discriminant function analysis shows that the
CQR5 can affectively detect 69% of low adherers to DMARDs using Fisher’s weighted regression equation.
Conclusion: A shortened version of the CQR increases the clinical utility by reducing the patient burden whilst
maintaining a good level of reliability and validity for a short, self-administered, self-report questionnaire.
Keywords: Rheumatoid arthritis, DMARDs, Medication adherence, Compliance, Questionnaire, Factor analysis
Background
As Rheumatoid Arthritis (RA) is currently incurable,
treatment is focused upon prevention of joint damage
and loss of function with typical therapies including
corticosteroids to reduce inflammation and DMARDs
to prevent joint damage [1]. Since DMARDs have been
shown to reduce disease activity and joint damage [2,3] it
is therefore essential to ensure that DMARDs are being
taken regularly and correctly in accordance with the cli-
nicians’ prescription to enhance efficacy for maintaining
joint function. However, it is well established that
DMARDs can take months to exhibit noticeable thera-
peutic benefits and can sometimes have unpleasant side-
effects that prompt patients to stop taking them [4].
The extent to which a patient takes medication as pre-
scribed is termed “adherence” [5]. A patient who is fully
adherent never (or rarely) misses or changes doses of
the prescribed medication. Suboptimal adherence can
lead to disease progression [6], increasing the burden on
the healthcare system due to GP and specialist appoint-
ments and hospitalisations as well as increased morbidity
and mortality [7]. The apparent treatment “failure” caused
by non-adherence can lead to unnecessary treatment es-
calation resulting in increased costs and decreased quality
of life [6-8]. Medication non-adherence in various chronic
illnesses is typically quoted at 30-50% [9,10]; however,
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non-adherence rates for DMARDs in RA are often higher
at 41% [11] and up to 75% for correct dosing [2,12].
The “gold standard” for measuring adherence is cur-
rently electronic medication event monitoring (eMEMs).
Medications are decanted into specialised pots with lids
equipped with microchips that automatically record the
time and date it was opened, thus inferring medication
taking. This allows for more accurate data regarding the
timing of doses than traditional methods such as pill
counts. However, eMEMs is expensive and requires nu-
merous resources from both the patient and researcher
for it to be implemented effectively. In addition, it is not
suitable for extended periods which can result in “white
coat compliance” where patients are deliberately more
adherent for a short period because they are aware that
their medication taking behaviour is being measured
[12]. This method is also unsuitable for polypharmacy,
limiting the ecological validity of medication taking in
RA where many patients are prescribed more than one
DMARD, which in itself creates challenges to adherent
behaviour. To increase the utility in large scale clinical
studies, the most common methods of assessing medica-
tion adherence are self-report questionnaires. Question-
naires can measure attitudes, intentions and behaviours
and although they are prone to biased results from so-
cially desirable answering, if item construction and vali-
dation is carried out correctly, these problems can be
overcome. An additional advantage of questionnaires is
that they can help to establish how and why a patient is
non-adherent which can then be addressed, whereas
eMEMs gives only the number of doses missed. Garber,
Nau, Erickson, Aikens & Lawrence [13] reviewed con-
cordance between self-reported adherence and more ob-
jective measures such as pill counts or eMEMs and
found that 55% of the questionnaires were highly con-
cordant with the objective measure. Of the self-report
measures that have been developed to monitor medica-
tion adherence, most have limited sensitivity and have
not been specifically developed for rheumatic diseases,
which present unique barriers and procedures for treat-
ment [14]. For this reason, the Compliance Question-
naire for Rheumatology (CQR19) was developed by de
Klerk et al. [12,15]. This questionnaire has been vali-
dated against eMEMs [12] and has been shown to have
good reliability and validity; however it can be consid-
ered lengthy for use in a clinical setting and the factor
structure of the questionnaire has not been published
which is necessary to aid reliability and interpretation.
Our aim therefore was to investigate whether it is pos-
sible to reduce the number of items in the CQR19 whilst
retaining the internal reliability. The rationale for shor-
tening the questionnaire was two-fold. Firstly, a con-
densed questionnaire would be quicker and easier to
administer during a routine outpatient clinic appointment
for strictly clinical uses and secondly, the reduction allows
for the CQR to be incorporated more easily into a battery
of questionnaires for research purposes.
Methods
Participants
Patients aged 18–80 years with a confirmed diagnosis of
Rheumatoid Arthritis and prescribed at least 1 DMARD
were opportunistically recruited from across rheumato-
logy outpatient clinics in the UK. Patients who were not
responsible for their own medication taking (i.e. relied
on a carer) or could not consent for themselves were
not eligible to participate.
The Compliance Questionnaire for Rheumatology (CQR19)
The CQR19 (Table 1) is a 19 item, self-administered ques-
tionnaire that was developed with the aim of correctly
Table 1 The full compliance questionnaire for
rheumatology (CQR19)
Questions
Q1 If the rheumatologist tells me to take the medicines, I do so
Q2* I take my anti-rheumatic medicines because I then have fewer
problems
Q3* I definitely don’t dare to miss my anti-rheumatic medications
Q4 If I can help myself with alternative therapies, I prefer that to
what my rheumatologist prescribes
Q5* My medicines are always stored in the same place and that’s
why I don’t forget them
Q6* I take my medicines because I have complete confidence in
my rheumatologist
Q7 The most important reason to take my anti-rheumatic medicines
is that I can still do what I want to do
Q8 I don’t like to take medicine. If I can do without them, I will
Q9 When I am on vacation, it sometimes happens that I don’t
take my medicines
Q10 I take my anti-rheumatic drugs, for otherwise what’s the point
of consulting a rheumatologist?
Q11 I don’t expect miracles from my anti-rheumatic medicines
Q12 If you can’t stand the medicines you might say: “throw it
away, no matter what”
Q13 If I don’t take my anti-rheumatic medicines regularly, the
inflammation returns
Q14 If I don’t take my anti-rheumatic medicines, my body warns me
Q15 My health goes above everything else and if I have to take
medicines to keep well, I will
Q16 I use a dose organizer for my medications
Q17* What the doctor tells me, I hang on to
Q18 If I don’t take my anti-rheumatic medicines, I have more
complaints
Q19 It happens every now and them, I go out for the weekend
and then I don’t take my medicines
Note: Items denoted with * have been retained in the final 5 item CQR5
questionnaire.
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identifying patients that were classified as “low” adherers
(taking <80% of their medication correctly) [12,15]. The
questions were identified through focus groups and clini-
cian’s expert opinion of the likely barriers to medication
taking. The four point Likert answering scale ranges from;
“Definitely don’t agree” (scored 1) to “Definitely agree”
(scored 4) with lower scores indicating lower levels of ad-
herence. The CQR19 was validated against eMEMs and
found to correctly identify 62% of low adherers without
the extensive time and costs that are associated with “gold
standard” medication monitoring techniques such as
pill counting or blood chemistry levels. An additional
advantage to the questionnaire is that the answers
can provide some indication of the social or cognitive
reasons behind non-adherence. When used in con-
junction with specialised psychosocial measures, this
provides the potential for healthcare professionals to
address problems identified by the questionnaire as
barriers to taking medication.
Methodology
All consecutive patients at 3 rheumatology clinics in the
UK were approached and asked if they would consent to
participate in a questionnaire study. Those that gave in-
formed consent were provided with a booklet of ques-
tionnaires, of which the CQR19 was one. Factor analysis
was then carried out on the responses in order to reduce
the number of items in the CQR19. Ethical approval for
this study has been given by the Hertfordshire Research
Ethics Committee (REC) of the UK NHS.
Statistical analyses
Exploratory factor analysis (EFA)
An exploratory factor analysis (EFA) was carried out on
the full CQR19 using SPSS v15 to identify the factor
structure and to aid reduction of the number of items
without losing reliability. The number of factors, the
amount of variance explained by each factor and the
amount of variance explained overall were each recorded
in order to compare successive models to ensure that
the explanatory ability of the questionnaire in a reduced
form was not compromised. Items were selected for re-
moval if they did not add explanatory power to the scale.
One item was removed at a time, the EFA procedure re-
peated, and each of the criteria above inspected again to
look for improvements in the reliability statistics. This
procedure was continued until the internal reliability
could no longer be improved by removing items.
The internal consistency measured by Cronbach’s α
and percentage of variance explained of the final reduced
model were evaluated against acceptable thresholds to en-
sure the model was stable before a confirmatory factor
analysis was carried out.
Confirmatory factor analysis (CFA)
As the data were categorical, new polychoric and asymp-
totic covariance matrices were created from which the
subsequent analyses were performed as there was a non-
normal response pattern. Datascreening was then carried
out in order to check for univariate and multivariate
normality and missing cases.
In contrast to the EFA where the factor structure is
dictated by the data, a confirmatory factor analysis
(CFA) tests whether or not the data fits a predefined
factor structure. Therefore, the CFA was testing whe-
ther the reduced questionnaire developed by the EFA
provided a good model fit to measure medication ad-
herence. The CFA was carried out using Lisrel 8. The re-
duced questionnaire was tested using Robust Maximum
Likelihood and the fit to the data was evaluated using
goodness of fit indices. These were chosen to include at
least one index from each fit class; absolute, parsimony
and comparative [16]. Taking into account the different
but important ways in which these fit indices evaluate
the model, including at least one of each gives the op-
portunity to fully consider the suitability of the model in
question.
Model modification was carried out using modification
indices provided by Lisrel and removing items with
standardized correlated residuals higher than ±2.00 and
R2 < 0.3 values indicating large error and little explana-
tion of medication adherence respectively [17]. For each
modification, the fit indices were again examined to de-
termine whether further modification was required.
The items that were retained in the final model were
checked to ensure that they explained more variance
than by chance. In this case, each item should have a
positive parameter estimate with a t value >1.96 (signifi-
cant to α = 0.05). The final model was tested in a ran-
dom sample of 500 created using the bootstrap test in
Stata with the “cfa” command [18].
Discriminant function analysis of CQR5
In order to test the discriminant ability of the CQR5,
each patient was classified as either a “high” or “low”
adherer, based on the regression model given by de
Klerk et al. [12]. A discriminant function analysis was
then carried out using SPSS v15. This determined whe-
ther the model can reliably distinguish between high and
low adherers. This test also gives the weights for each
question to create a regression equation to be used with
the reduced questionnaire to optimise classification.
Results
Participants
A total of 225 patients completed the CQR19. A total
sample size of 225 gives a-cases-per-predictor ratio for the
exploratory factor analysis of 12:1 which is in keeping with
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general rules of thumb suggested for this type of analysis
[19]. The median age range was 50–59 years and 75.1%
were female (see Table 2). Methotrexate was the most
commonly prescribed DMARD (54%).
Exploratory factor analysis of CQR19
The initial EFA of the CQR19 showed 6 eigen-values >1
which accounted for 61.6% of the variance in adherence,
which is somewhat higher than the original authors
found at 46% [12]. The Kaiser-Meyer-Olkin Measure of
Sampling Adequacy (KMO) = 0.79 which indicates a
weak factor structure [20]. This can also be seen as the
eigen-values of two of the factors were very low at 1.09
and 1.04, a trait which is enhanced by the fact that the
factor matrix indicated that only one item loaded highly
on each of factors 2–6 suggesting that the additional fac-
tors were the product of items that inadequately measure
medication adherence (see Additional file 1: Table S1).
A single factor is also suggested by the Scree Plot in
Figure 1.
The reduction of items led to a gradual increase in
KMO and reduction in the number of factors, suggesting
that the presence of more than one factor was an arte-
fact of a few questions that in this case do not appear to
be measuring the construct of medication adherence.
This is supported by the fact that the percentage of
variance in medication adherence explained by the ques-
tionnaire reduces by only 11% (from 61.6% to 50.3%) on
removal of 8 items, and subsequently 4 factors. The re-
sults of the factor analyses are summarised in Table 3.
The final model that was identified from the EFA was
the CQR11 which had only one factor. This showed both
a good KMO (0.84) and Cronbach’s α (0.84), indicating a
strong factor structure and reliable measure. This model
explained 50.3% of the overall variance in medication ad-
herence, and has the benefit of being short and robust.
The items retained were; 2, 3, 5, 6, 7, 10, 13, 14, 15, 17, 18.
Confirmatory factor analysis of CQR11
Datascreening of the polychoric and asymptotic corre-
lation matrices showed that there were 11 missing values
and 1 missing case. Once listwise deletion had been
implemented, the resulting effective sample size was N =
187 giving a cases per predictor ratio of 18:1. Of these
187 cases, there were 154 distinct response patterns, in-
dicating that the majority of participants responded
completely differently to everybody else. The two most
common patterns were; i) answering “strongly agree” to
every question (N = 17) and ii) answering “agree” to
every question (N = 7). A similar pattern was not found
with the “disagree” responses; therefore it is possible that
these participants were showing social response bias as
“agree” responses indicate high adherence rates. How-
ever, the bivariate normality appeared to hold with
nearly all of the p values being non-significant and two
being very close to non-significant (item 10 vs item 2,
p = 0.01 and item 18 vs item 3, p = 0.03).
The CQR11 model that was identified from the Ex-
ploratory Factor Analysis showed a less than satisfactory
fit as the Satorra-Bentler χ2 and Root Mean Square Error
(RMSEA) were outside of the acceptable ranges (see
Table 4 and footnote for recommended cut off values).
Model modification was therefore carried out using modi-
fication indices provided by Lisrel and removal of items
with residuals of more than ±2.00 or where R2 < 0.3, to
improve the model fit. Through subsequent modifications,
it was found that 6 items consistently had the highest
standardised residuals and the lowest R2 values, indicating
that these items produced the most error and explained
little of the variance in medication adherence. For these
reasons, they were removed from the model to produce
the CQR5 (see Table 1 for items retained in the CQR5).
The fit indices for the CQR5 were much improved on
the CQR11 and showed an acceptable model. The fit in-
dices were all within acceptable parameters; RMSEA =
0.089 (95% CI, 0.036:0.15), NFI = 0.98, CFI = 0.99 and
RMR = 0.054 indicating a good fit to the data. Although
the χ2 values were beyond those acceptable for a good
fit, these are susceptible to sample sizes >100 making
p > 0.05 overly sensitive and so should be interpreted in
Table 2 Demographics of participating patients
N Percentage
Total sample size 225
Gender
Male 52 23.1
Female 169 75.1
Missing 4 1.8
Age category
18–29 6 2.6
30–39 20 8.8
40–49 35 15.6
50–59 50 22.2
60–69 66 29.3
70+ 44 19.6
Missing 4 1.8
Disease duration
<1 year 1 0.4
1–4 years 46 20.4
5–9 years 77 34.2
10–19 years 53 23.5
20–29 years 16 7.1
30+ years 19 8.4
Missing 12 5.3
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conjunction with other indices [21]. All of the t-values
for the parameter estimates were positive and highly sig-
nificant, which is indicated by the large parameter esti-
mates shown in Figure 2. The R2 values for the parameter
estimates ranged from R2 = 0.65 (Q17) to R2 = 0.84 (Q6)
showing that each of the items explained a large amount
of variance in medication adherence. The internal reliabi-
lity was acceptable as Cronbach’s α = 0.85. The goodness
of fit indices remained adequate in a bootstrapped sample
of 500 randomly selected samples from the dataset.
Discriminant function analysis
A discriminant function analysis was carried out using
the CQR5 to identify the ideal weighted combination of
items to identify high and low adherers measured by the
full CQR19. The canonical linear discriminant analysis
was highly significant, F(5, 228) = 45.10, p < 0.001, in-
dicating that the CQR5 can effectively discriminate
between high and low adherers. The effect size η2 was
large at 0.50 and the explained variance was very high at
70.5%. The structure matrix indicates that Q3 (0.84),
Q17 (0.30) and Q5 (0.20) were most strongly correlated
with the function of adherence. This is supported by a
one way ANOVA of the item means between groups
which shows that these questions produce significantly
lower means by patients classified as low adherers, indi-
cating that they “do not agree” more often than those
classified as high adherers.
The CQR5 correctly predicted group membership mea-
sured by the full CQR19 for 88.5% of cases, with sensi-
tivity to predict low adherence of 69% and specificity of
predicting high adherence of 97%.
Table 3 Results of exploratory factor analyses when removing items
Factor
analysis
Item
removed
MSA of
removed item
Kaiser-Meyer-Olkin Number
of factors
Highest
eigen value
Ratio of first to
second eigen values
Cumulative
percentage of
variance explained
CQR19 - - 0.79 6 4.48 2.86 61.61
CQR18 11 0.39 0.80 6 4.96 2.57 64.00
CQR17 16 0.52 0.81 5 4.92 2.55 60.87
CQR16 19 0.67 0.83 4 4.79 2.97 54.92
CQR15 12 0.69 0.83 4 4.71 3.16 56.20
CQR14 9 0.68 0.84 3 4.65 3.39 51.05
CQR13 8 0.66 0.85 3 4.60 3.37 53.69
CQR12 1 0.82 0.84 2 4.30 3.36 54.97
CQR11 4 0.86 0.84 1 4.26 - 50.36
Figure 1 Scree plot of the CQR19.
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The structure matrix gives the optimal linear combi-
nation of the CQR5 questions to maximise the discri-
minant ability. Fisher’s classification function coefficients
result in the following equations:
D0 ¼ −27:611þ 4:407 Q2ð Þ þ 0:939 Q3ð Þ
þ 6:101 Q5ð Þ þ 2:366 Q6ð Þ þ 2:531 Q17ð Þ
ð1Þ
D1 ¼ −33:304þ 2:801 Q2ð Þ þ 5:008 Q3ð Þ
þ 6:471 Q5ð Þ þ 1:215 Q6ð Þ þ 3:252 Q17ð Þ
ð2Þ
Given the two parameters D0 and D1, if D0 is greater
than D1 then the respondent should be classified as
likely to be a low adherer. Conversely, if D1 is greater
than D0 then the respondent should be classified as
likely to be highly adherent. See Additional file 2.
Discussion
The present study found that reducing the CQR to just
5 items did not dramatically reduce its explanatory
power and the sensitivity of identifying low adherers
remained high. The exploratory factor analysis allowed
for the factor structure to be made simpler and more ro-
bust with the removal of extraneous items. This reduces
the burden on patients whilst completing the question-
naire, and makes interpretation easier as all items can be
reliably considered to be related to adherence.
The confirmatory factor analysis confirms that the
CQR5 fits the data well and explains 52.9% of variance
in medication adherence which is good for a very short,
self-administered questionnaire. The CQR5 also per-
formed at a similar rate in a bootstrapped sample of 500
repetitions, confirming that the scale had not been over-
fitted ad hoc to this particular dataset, but that it is likely
to be applicable to the wider RA population.
Further evidence of this generalisability is shown by
the fact that two of the items identified in the CQR5
Table 4 Confirmatory factor analysis goodness of fit statistics
Model χ2 Satorra-Bentler χ2 RMSEA (90% CI) NFI CFI RMR
CQR11 465.34** 172.05** 0.11 (0.095;0.13) 0.94 0.95 0.094
CQR5 56.64** 14.14* 0.089 (0.036;0.15) 0.98 0.99 0.054
** = p < 0.001.
* = p < 0.05.
For the purposes of this analysis, the following fit indices were used with the respective cut off values as recommended by Hu and Bentler [21]. Absolute fit class;
χ2 and Satorra-Bentler Scaled χ2 because the latter adjusts for polychoric correlation (p > .05), Root Mean square Residual (RMR; <.08). Parsimony fit class; Root
Mean Square Error of Approximation (RMSEA; <.08). Comparative fit class; Normed Fit Index (NFI; >.9) and Comparative Fit Index (CFI; >.9).
Figure 2 Path diagram for CQR5.
Hughes et al. BMC Musculoskeletal Disorders 2013, 14:286 Page 6 of 8
http://www.biomedcentral.com/1471-2474/14/286
(Q3 and Q5) correspond to two of the four items that
the original authors found to explain 35% of the variance
in their sample [12]. As the full CQR19 only explained
46% of the variance in their sample, these items are
clearly contributing highly to the explanation of medica-
tion adherence.
It is interesting to note that all six of the reversed
items were removed from the questionnaire by the EFA.
This suggests that there was a fundamental problem
with the delivery of these questions that led to them not
explaining non-adherence in an adequate way. Four of
these six items explore issues of medications in general
and the patients’ expectations of their medications.
These constructs are well measured in Horne et al.
[22] Belief ’s about Medications Questionnaire (BMQ)
which has been tested and found to be reliable and valid
across a number of illnesses including RA [23]. It could
therefore be suggested that the BMQ should be used in
conjunction with the CQR to specifically address this
construct. The two other reversed items are concerned
with reduced medication adherence on weekends and
holidays. Unsurprisingly, it was found that these two
items were strongly correlated, although neither of them
correlated strongly with any other item. It was interes-
ting to find that Q9; “When I am on vacation, it some-
times happens that I don’t take my medications” showed
no correlation to Q14; “If I don’t take my anti-rheumatic
medication regularly, the inflammation returns”. This
could be due to the fact that either patients had not
experienced taking a holiday whilst on their current
DMARD, or that patients view their holidays as com-
pletely separate to their normal lives and develop a new
routine that is unconcerned with their disease status.
This possibly changing belief would be interesting to in-
vestigate in a more formal way, particularly if it leads to
low levels of adherence whilst away from patients’ nor-
mal care teams.
The discriminant function analysis of the CQR5 sug-
gests good specificity by identifying 97% of the high
adherers classified by the full CQR19 and sensitivity of
69% at identifying low adherers. As the CQR5 is a nested
model of the CQR19, which was used as the dependent
variable to classify patients, good sensitivity and speci-
ficity would be expected. However, the good discri-
minatory power that the CQR5 shows provides more
evidence that the other 14 items of the CQR19 are ex-
traneous and are not providing additional explanatory
power over and above the five retained items, demon-
strating the clinical utility of the more parsimonious
questionnaire. The CQR5 performs equally as well as the
CQR19 at correctly classifying patients, but with only a
quarter of the number of questions. However, as the
CQR19 was used as the dependent variable for the dis-
criminant function analysis, the sensitivity and specificity
of the CQR5 should be interpreted with caution unless it
is shown to be as good when using an objective mea-
sure of adherence (such as electronic medication event
monitoring) as the dependent variable.
As was found by de Klerk et al. [12], the CQR5 is
most predictive when used as a weighted discriminant
equation. This is the optimum combination of weighted
questions to classify patients as either high or low ad-
herers, and is the function that should be used when
implementing the CQR5. The structure matrix indi-
cates that Q3; “I definitely don’t dare to miss my anti-
rheumatic medication” is the most indicative of high or
low adherence as high adherers tend to “agree” whereas
low adherers tend to “disagree”. It may therefore be pos-
sible to get an indication of the overall result from the
answer to this question with a positive (answer 3 or 4)
response indicating high adherence and a negative (an-
swer 1 or 2) response indicating low adherence. The
main benefit of using self report questionnaires is to at-
tempt to identify the determinants of non-adherence in
order to target for intervention. Although the CQR is
not designed for this purpose, it does allow for the latent
variable of adherence to be measured alongside validated
measures of adherence predictors. Questionnaires such
as the revised Illness Perception Questionnaire (IPQ-R)
[24] and the Beliefs about Medications Questionnaire
(BMQ) [22] have shown promising strides in identifying
determinants of non-adherence in many illnesses includ-
ing Rheumatoid Arthritis [23-26]. The CQR5 can be
used in future research as a short, parsimonious, unidi-
mensional adherence scale to successfully identify the
most useful areas for intervention with the ultimate aim
of improving patient outcomes.
This study benefitted from having a large sample size
and patients that had a wide range of disease and treat-
ment experience as well as differing socio and geo-
graphic demographics and ages. Although the CQR5
performed well compared to the CQR19, the next step
would be to validate the reduced version against a meas-
ure of adherence such as eMEMs to determine the sen-
sitivity of identifying suboptimal adherence in a more
objective manner. However, some support is given by
the fact that within this sample of 225 patients, 24%
(N = 53) were classified as being low adherers based
on their CQR5 scores which is in accordance with
previously published figures [5,12,23,27] of medication
non-adherence.
Conclusions
This study shows that it is possible to reduce the num-
ber of questions of the CQR19 without losing its ex-
planatory properties, thus improving the clinical utility.
The CQR5 is as good as the CQR19 at classifying pa-
tients as low adherers and is quick and easy enough to
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be widely used in the clinic without burdening patients.
The simplified factor structure is also more parsimoni-
ous and gives an indication to the clinical care team of
possible sub-optimal DMARD adherence which can then
be addressed. This then has the potential to improve the
prognosis for the patient and avoid unnecessary treat-
ment escalations or delays.
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